Sage Mountain Advisors’s GSK GSK Stock Holding History

Sage Mountain Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,193	Closed	-$206K	–	411
2025 Q4	$206K	Buy	+4,193	New	+$196K	0.01%	472

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Sage Mountain Advisors's GSK Position: Q1 2026 in Review

Sage Mountain Advisors sold out of GSK (GSK) in Q1 2026, closing a stake of 4,193 shares — an estimated $206K sold.

Sage Mountain Advisors first reported a position in GSK in Q4 2025 and held it in 1 quarter. The position peaked at $206K in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Sage Mountain Advisors reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Sage Mountain Advisors sold 4,193 GSK shares in Q1 2026, an estimated $206K.
Sage Mountain Advisors first reported a position in GSK in Q4 2025 and held it in 1 quarter.
Sage Mountain Advisors's GSK position peaked at $206K in Q4 2025.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Sage Mountain Advisors's 13F filing for Q1 2026, filed 11 May 2026.